Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) Enterprise Value (2026)

Updated

Aktis Oncology's Enterprise Value was $1.02 billion in Q3 2026, down 38.1% from the prior quarter.

Analysis

Aktis Oncology (AKTS) Enterprise Value (2026) Analysis & Trends

On a trailing twelve-month basis, Aktis Oncology's Enterprise Value was $523.27 million through Sep 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 Aktis Oncology 895.95 Mn 335.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 1.02 Bn
Jun 30, 2026 1.64 Bn
Mar 31, 2026 583.75 Mn
API Access

Aktis Oncology Enterprise Value API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=enterprise-value&ticker=AKTS&period=max&api_key=YOUR_API_KEY